Tachyphylaxis after Botox

Botulinum toxin type A, colloquially referred to as botox, is a protein neurotoxin produced by the bacterium Clostridium botulinum. After binding to the cholinergic nerve ending, it is internalized. Its enzymatic light chain cleaves the SNAP-25 protein, which belongs to the SNARE complex responsible for acetylcholine release. The result is a temporary reduction in neuromuscular transmission and a decrease in the contraction strength of the selected muscle.

The effect gradually subsides as functional nerve endings regenerate and neuromuscular junctions are reformed. This is a physiological waning of the product's effect, not tachyphylaxis. Secondary non-responsiveness is defined as a situation where the patient initially responded properly, but subsequent properly performed procedures have ceased to provide a comparable effect.

Secondary ineffectiveness can be:

• partial, when the result is weaker, covers a smaller area, or lasts for a shorter period;
• complete, when no clinically detectable muscle weakness occurs after administering an appropriate dose;
• immunological, related to antibodies neutralizing the active neurotoxin;
• non-immunological, resulting, among other factors, from improper patient qualification, dose, technique, product storage, or changes in muscle anatomy and activity.

A mere shortening of the duration of action from several months to a slightly shorter period is not sufficient to diagnose immunoresistance. Evaluation of the effect should take into account standardized photographs, contraction strength before and after the procedure, dosage, and time elapsed since the injection. Antibodies can be detected using laboratory methods; however, binding assays, such as ELISA, do not distinguish neutralizing from non-neutralizing antibodies. Biological assays are more reliable, but their availability in routine practice is limited.

There is no specific number of treatments after which tachyphylaxis develops. In most aesthetically treated patients, neutralizing antibodies do not form even after many properly planned cycles. The risk also cannot be reliably predicted solely on the basis of age, sex, or duration of therapy.

Isolated cases of partial secondary non-response have been described after just a few exposures, but more frequently the problem emerged after repeated treatments performed over several years. In case reports, the time to antibody detection was highly variable, ranging from a few months to several years. These data do not allow for determining a safe threshold for the number of injections.

More significant than the number of treatments itself are:

• total lifetime dose received;
• dose size during a single session;
• intervals between subsequent administrations;
• administering so-called boosters, i.e., additional injections after a few weeks;
• simultaneous treatment of multiple aesthetic or therapeutic areas;
• immunogenic properties of the specific product;
• individual immunological predisposition of the patient.

An early warning sign may be dose creep, which is the need to gradually increase the dose, and interval creep, which is an increasingly rapid return of muscle activity and the shortening of intervals between treatments. However, these symptoms do not conclusively determine the presence of antibodies. Prior to making such a diagnosis, it should be assessed whether an adequate dose, the appropriate product, and correct injection sites were used, and whether the issue indeed remains a dynamic wrinkle.

The risk cannot be eliminated completely, but immune exposure can be reduced without compromising the safety and quality of treatment. The most important principles include:

• using the lowest effective dose, tailored to anatomy and muscle strength;
• maintaining appropriate intervals between full sessions, usually around 12 weeks or longer if the effect still persists;
• avoiding routine boosters and frequent minor touch-ups;
• limiting unjustified treatment of multiple areas during a single session;
• selecting an approved, properly stored product with the lowest possible antigenic load;
• maintaining documentation that includes the product name, batch number, dose, dilution, injection points, and clinical effect;
• taking into account all exposures to BoNT-A, including in the treatment of bruxism, migraine, and hyperhidrosis.

At Ambasada Urody, botulinum toxin is used for smoothing expression lines, lifting facial features, mesobotox, and the French Lip Flip, as well as in therapeutic treatments for bruxism, migraine, and hyperhidrosis. Each of these procedures increases the total exposure to the neurotoxin; therefore, the treatment plan should take into account all indications, not just procedures performed on the face. Mesobotox also contains botulinum toxin and is not a way to bypass confirmed immunoresistance.

If the toxin does not work or its continued administration is not recommended, established signs of aging can be corrected using methods independent of neuromuscular transmission. In the available offering, these include: hyaluronic acid fillers, tissue stimulators, calcium hydroxyapatite, polylactic acid, lifting threads, fractional laser, laser peel, microneedling radiofrequency, needle mesotherapy, Dermapen 4.0, microdermabrasion, hydrodermabrasion, acid peels, peels with iontophoresis, endermologie, and Icoone. These methods can improve skin volume, density, or surface, but they do not replace the action of the toxin on excessive muscle activity. The choice of treatment should result from identifying the dominant mechanism of the wrinkles.